These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 7679828

  • 1. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
    [No Abstract] [Full Text] [Related]

  • 2. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
    [Abstract] [Full Text] [Related]

  • 3. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract] [Full Text] [Related]

  • 6. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 8. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC, Theilmann L.
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract] [Full Text] [Related]

  • 9. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.
    Ferraresso M, Ghio L, Edefonti A, Garavaglia R, Berardinelli L.
    Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478
    [Abstract] [Full Text] [Related]

  • 10. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.
    Abouljoud MS, Levy MF, Klintmalm GB.
    Transplant Proc; 1995 Feb; 27(1):1121-3. PubMed ID: 7533360
    [No Abstract] [Full Text] [Related]

  • 11. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [Abstract] [Full Text] [Related]

  • 12. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

  • 13. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L.
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract] [Full Text] [Related]

  • 14. FK 506 treatment of intractable rejection after liver transplantation.
    Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
    [No Abstract] [Full Text] [Related]

  • 15. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection.
    Lewis WD, Jenkins RL, Burke PA, Winn KM, Shaffer D, Lopez R, Monaco AP.
    Transplant Proc; 1991 Dec; 23(6):2989-91. PubMed ID: 1721336
    [No Abstract] [Full Text] [Related]

  • 16. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP, Tullius SG, Mueller AR, Schumacher G, Nüssler N, Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract] [Full Text] [Related]

  • 17. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.